ANI Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. This is an annual filing, not a standalone fourth-quarter report. ANI develops, manufactures, and markets branded and generic pharmaceuticals. Its Rare Disease segment currently centers on Purified Cortrophin Gel.
Financial results
| Metric | 2023 | 2022 |
|---|---|---|
| Net revenue | $486.8 million | $316.4 million |
| Operating income (loss) | $47.0 million | $(35.3) million |
| Net income (loss) | $18.8 million | $(47.9) million |
| Diluted earnings (loss) per share | $0.85 | $(3.05) |
| Cash from (used in) operations | $119.0 million | $(31.2) million |
| Cash and cash equivalents at year-end | $221.1 million | $48.2 million |
- Revenue grew 53.9%. Generics, Established Brands, and Other revenue rose 36.4% to $374.7 million; Rare Disease revenue rose 169.0% to $112.1 million, entirely from Cortrophin Gel.
- Cost of sales excluding depreciation and amortization was 37.3% of revenue, versus 43.9% in 2022; the corresponding margin was 62.7%. Operating margin was 9.6%, compared with an operating loss margin of 11.2% in 2022. Net margin was 3.9%, versus a net loss margin of 15.2%.
- R&D expense increased 53.6% to $34.3 million; selling, general, and administrative expense increased 30.4% to $161.7 million. Management attributed the increases primarily to development activity, employment costs, rare-disease commercialization, legal expenses, and business growth.
- Investing cash outflow was $18.5 million, including $8.9 million of capital expenditures and $9.6 million for acquired product rights. Financing cash inflow was $67.4 million, principally reflecting $80.6 million of net proceeds from a May 2023 stock offering.
- Year-end debt principal was $294.0 million under the term loan; $40.0 million remained available on the undrawn revolving facility. The term loan’s stated rate was 11.46% at year-end. The company reported a 3.6 working-capital ratio and said resources should cover requirements and debt obligations for at least 12 months.
Material changes and notable items
- ANI returned to profitability and generated positive operating cash flow, versus losses and operating cash use in 2022. Cortrophin Gel’s second launch year and growth in generic and established-brand products contributed to higher revenue.
- In October 2023, FDA approved and ANI launched a 1-mL Cortrophin Gel vial for adjunctive treatment of certain acute gouty arthritis flares. ANI also acquired generic applications and product rights during the year.
- ANI issued 2.18 million common shares in May 2023, raising $80.6 million net. Common shares outstanding increased to 20.7 million at year-end from 17.6 million a year earlier.
- ANI closed its Oakville, Ontario facility in March 2023 and completed the transfer of its products to U.S. sites. A February 2024 sale agreement set a price of C$19.2 million, approximately US$14.2 million; closing was expected by the end of March 2024.
- The company reported that material weaknesses in Novitium controls and certain IT access controls, identified in the prior year, were remediated by December 31, 2023. Management and the auditor concluded internal control over financial reporting was effective at year-end.
Outlook, risks, and contingencies
- No quantified revenue or earnings guidance is provided. Management intends to continue investing in Cortrophin Gel and its Rare Disease platform, developing generics, and considering acquisitions. It expects the blended Merck royalty rate on Cortrophin Gel sales to be in the upper teens in 2024, potentially reaching the low 20% range if revenue grows significantly beyond 2024.
- Key risks include Cortrophin Gel’s ability to sustain commercial growth; competition and generic price erosion; reliance on limited or single-source API suppliers and contract manufacturers; regulatory, quality, and controlled-substance requirements; and concentration in customers. Four customers generated 69% of 2023 revenue and held about 81% of year-end net receivables.
- Three products marketed without approved NDAs or ANDAs generated $22.4 million of 2023 revenue. ANI warns that FDA action could require approval applications or withdrawal. Hyoscyamine, also without an approved application, was acquired in December 2023 and was planned for commercial launch in early 2024.
- Government pricing and reimbursement changes, including the removal of the Medicaid rebate cap from January 2024 and Medicare changes under the Inflation Reduction Act, could raise rebates or pressure prices. Chargeback estimates are significant: the year-end accrual was $84.2 million and was identified as the audit’s critical audit matter. Management estimates a 1% change in chargeback estimates would affect 2023 revenue by $5.9 million.
- Debt is secured by substantially all relevant assets and carries financial covenants. Variable-rate exposure remains despite a swap covering $139.4 million notional at year-end. The company also has $24.0 million of remaining contingent consideration at year-end; it paid $12.5 million in December 2023 and another $12.5 million in February 2024.
- Legal matters include an appeal in Bystolic antitrust litigation, a pending patent suit concerning proposed pitolisant, and ranitidine-related litigation involving Novitium. ANI disputes liability; the filing does not provide a clear estimate of reasonably possible material losses. Separately, CG Oncology disputed ANI’s royalty rights in February 2024; ANI held 219,925 CG Oncology shares valued at about $10.2 million as of February 27, 2024.
- Related-party payments to entities in which Novitium executives hold interests totaled $11.9 million in 2023, primarily for clinical research and API supply. The filing also describes earn-out payments to Novitium members, including related parties.
Important facts for investors to verify
- Whether Cortrophin Gel growth, market access, and the new vial indication can support continued revenue growth after the launch ramp.
- How customer concentration, chargebacks, rebates, returns, and collection timing affect net revenue, receivables, and operating cash flow.
- The term-loan amortization and refinancing profile, interest expense at prevailing rates, covenant headroom, and use of the $40.0 million revolver.
- Completion and proceeds of the Oakville sale, and the financial and commercial impact of the CG Oncology royalty dispute.
- Developments in the disclosed litigation and regulatory matters, including unapproved products, and whether any additional loss accrual or disclosure becomes necessary.